Advertisement

Topics

PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability

20:00 EDT 21 Aug 2017 | JAMA

Cardiovascular medicine is struggling with the new proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor drugs for lowering low-density lipoprotein cholesterol (LDL), not primarily because of efficacy concerns or safety issues, but because the price of these new agents exceeds $14 000 a year. While clinicians are seeking to understand how best to exploit the potential for enhanced protection these drugs may provide to patients at risk of atherosclerotic complications (such as myocardial infarction and stroke), payers are focused on constraining the use of these medications, recognizing that the pool of candidates for PCSK9 inhibitor drugs is enormous.

Original Article: PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability

NEXT ARTICLE

More From BioPortfolio on "PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...